New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 8, 2013
13:31 EDTTHLDThreshold Pharmaceuticals reports TH-302 data at ASH
Threshold Pharmaceuticals announced that clinical data from two early-stage trials of TH-302, its investigational hypoxia-targeted drug, will be presented at the 55th Annual Meeting of the American Society of Hematology, ASH, taking place December 7 - 10, New Orleans. Results from the dose escalation component of a Phase 1/2 clinical trial of TH-302 in combination with dexamethasone in patients with relapsed and/or refractory multiple myeloma will be presented in a poster session on Saturday evening, Abstract #1948. Fourteen patients initiated therapy, all having received 3 to 11 prior treatments [median of 6.5] and all having received a regimen containing Velcade (bortezomib, a first-in-class proteasome inhibitor), an immunomodulatory agent [Revlimid (lenalidomide) and/or Thalomid (thalidomide)], and an alkylating agent. "There are few treatment options for patients with advanced multiple myeloma who stop responding to bortezomib and lenalidomide, and responses to subsequent salvage therapy have historically been extremely low," said Irene Ghobrial, M.D., Associate Professor of Medicine at Dana-Farber Cancer Institute, who led the study and will present the results at ASH. "The preliminary results suggest that the combination of TH-302 with dexamethasone is active in some heavily pretreated patients who stop responding to conventional therapy."
News For THLD From The Last 14 Days
Check below for free stories on THLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2014
07:45 EDTTHLDThreshold Pharmaceuticals should be bought ahead of data, says Stifel
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use